MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

Toripalimab, a humanized monoclonal antibody against PD-1, was approved for treatment of previously treated advanced melanoma and nasopharyngeal carcinoma. Here, we report the results of CHOICE-01 (NCT03856411), a randomized, double-blind Phase 3 trial of toripalimab in combination first-line chemotherapy for advanced non-small cell lung cancer (NSCLC).